Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3274948 | Médecine des Maladies Métaboliques | 2013 | 5 Pages |
Abstract
Basal insulin analogues aim at mimicking basal physiologic insulin needs. Consistently, a new-generation of basal insulin has been developed: insulin degludec. This molecule has the ability to self-assemble into multihexamers following subcutaneous administration, which results in a very protracted absorption rate. Pharmacokinetics studies in patients with type 1 and type 2 diabetes receiving insulin degludec once daily have shown that insulin degludec has flat and stable pharmacokinetics profile with an ultra-long duration of action (>42Â h).
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
B. Cariou,